Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, ...

The Bank of Japan’s massive program of quantitative easing, begun in 2013 and at its height involving annual purchases of ¥50 ...

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of ...

Southern's diversified energy mix and strategic shift toward renewables position it well for long-term stability and ...

After President Donald Trump’s inauguration in January, there was a brief, vulgar trend floating around TikTok: “#FAFO.” ...

Apple Inc. faces challenges from AI disrupting its hardware moat. Click for how AAPL management is facing moat degradation ...

The panel is not expected to change rates, but the dot plot will be watched to see if the Fed's prior projection of two rate ...

The company develops and distributes medical technologies across various therapeutic areas. As a member of both the S&P 500 ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

South Korean President Lee Jae-myung departed for Canada on Monday to attend the Group of Seven summit, his first overseas ...

The Enhanced Games don't just allow performance-enhancing drugs (PEDs), but celebrate their use in targeting world records in ...